



25.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Scott S. Graves et al.

Title: HUMANIZED ANTIBODIES THAT BIND TO THE ANTIGEN BOUND BY ANTIBODY NR-LU-13 AND THEIR USE IN PRETARGETING METHODS

Docket No.: 295.061US4

Serial No.: 10/787,067

Filed: February 25, 2004

Due Date: N/A

Examiner: Unknown

Group Art Unit: 1642

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

☒ A return postcard.

☒ A Communication Concerning Related Applications (1 pg.).

☒ An Information Disclosure Statement (2 pgs.), Form 1449 (7 pgs.).

If not provided for in a separate paper filed herewith, Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.


Customer Number 21186


By: 

Atty: Peter L. Malen

Reg. No. 44,894

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 26th day of January, 2005.


Name


Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

(GENERAL)



S/N 10/787,067

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Scott S. Graves et al.	Examiner:	Unknown
Serial No.:	10/787,067	Group Art Unit:	1642
Filed:	February 25, 2004	Docket:	295.061US4
Title:	HUMANIZED ANTIBODIES THAT BIND TO THE ANTIGEN BOUND BY ANTIBODY NR-LU-13 AND THEIR USE IN PRETARGETING METHODS		

INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. § 1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

Pursuant to 37 C.F.R. § 1.98(d), copies of the listed documents are not provided as these documents were previously cited by or submitted to the U.S. Patent Office in connection with Applicants' prior U.S. application, Serial No. 10/056,794, filed on January 24, 2002, which is relied upon for an earlier filing date under 35 U.S.C. § 120.


The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,
SCOTT S. GRAVES ET AL.
By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 371-2110

Date January 25, 2005

By



Peter L. Malen
Reg. No. 44,894

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 25th day of January, 2005.

Dawn M. Rode
Name

Dawn M. Rode
Signature



S/N 10/787,067

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Scott S. Graves et al. Examiner: Unknown
Serial No.: 10/787,067 Group Art Unit: 1642
Filed: February 25, 2004 Docket: 295.061US4
Title: HUMANIZED ANTIBODIES THAT BIND TO THE ANTIGEN BOUND BY
ANTIBODY NR-LU-13 AND THEIR USE IN PRETARGETING METHODS

COMMUNICATION CONCERNING RELATED APPLICATION(S)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants would like to bring to the Examiner's attention the following related applications in the above-identified patent application:

<u>Serial/Patent No.</u>	<u>Filing Date</u>	<u>Attorney Docket</u>	<u>Title</u>
08/871,488 6,358,710	June 9, 1997	295.061US1	HUMANIZED ANTIBODIES THAT BIND TO THE ANTIGEN BOUND BY ANTIBODY NR-LU-13 AND THEIR USE IN PRETARGETING METHODS
10/056,794	January 24, 2002	295.061US2	METHOD OF REDUCING IMMUNOGENICITY OF TOXICITY OF AN ANTIBODY OF IgG CLASS
10/631,660	July 31, 2003	295.061US3	METHODS OF USE OF ANTIBODIES WITH REDUCED IMMUNOGENICITY

Respectfully submitted,
SCOTT S. GRAVES ET AL.
By Applicants' Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 371-2110

Date

January 25, 2005

By

Peter L. Malen
Reg. No. 44,894

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 26th day of January 2005.

Name

Dawn M. Poole


Signature

Dawn M. Poole

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Complete if Known

Application Number	10/787,067
Filing Date	February 25, 2004
First Named Inventor	Graves, Scott
Group Art Unit	1642
Examiner Name	Unknown

Sheet 1 of 7

Attorney Docket No: 295.061US4

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document
	4,237,224	12/02/1980	Cohen et al.
	4,399,216	08/16/1983	Axel et al.
	4,468,464	08/28/1984	Cohen et al.
	4,634,665	01/06/1987	Axel et al.
	4,656,134	04/07/1987	Ringold
	4,740,470	04/26/1988	Cohen et al.
	4,816,397	03/28/1889	Boss et al.
	4,816,567	03/28/1989	Cabilly et al.
	4,870,023	09/26/1989	Fraser et al.
	4,879,236	11/07/1989	Smith et al.
	4,946,778	08/07/1990	Ladner et al.
	4,975,369	12/04/1990	Beavers et al.
	5,015,580	05/14/1991	Christou et al.
	5,041,379	08/20/1991	Fraser et al.
	5,071,748	12/10/1991	Miller
	5,077,214	12/31/1991	Guarino et al.
	5,084,396	01/28/1992	Morgan et al.
	5,091,513	02/25/1992	Huston et al.
	5,110,729	05/05/1992	Maeda et al.
	5,120,657	06/09/1992	McCabe et al.
	5,122,458	06/16/1992	Post et al.
	5,132,405	07/21/1992	Huston et al.
	5,147,788	09/15/1992	Page et al.
	5,149,655	09/22/1992	McCabe et al.
	5,155,037	10/13/1992	Summers
	5,162,222	11/10/1992	Guarino et al.
	5,169,784	12/08/1992	Summers et al.
	5,169,939	12/08/1992	Geffer et al.
	5,179,007	01/12/1993	Jarvis et al.
	5,179,017	01/12/1993	Axel et al.
	5,185,254	02/09/1993	Linnenbach,
	5,202,422	04/13/1993	Hiatt et al.
	5,225,539	07/06/1993	Winter
	5,260,203	11/09/1993	Ladner et al.
	5,266,314	11/30/1993	Maeda
	5,304,489	04/19/1994	Rosen
	5,322,774	06/21/1994	Peakman et al.
	5,348,886	09/20/1994	Lee et al.
	5,348,887	09/20/1994	Bumol et al.
	5,349,053	09/20/1994	Landolfi

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Sheet 2 of 7

Complete if Known

Application Number	10/787,067
Filing Date	February 25, 2004
First Named Inventor	Graves, Scott
Group Art Unit	1642
Examiner Name	Unknown

Attorney Docket No: 295.061US4

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document
	5,385,839	01/31/1995	Stinski
	5,405,779	04/11/1995	McCabe et al.
	5,413,923	05/09/1995	Kucherlapati et al.
	5,422,281	06/06/1995	Harris et al.
	5,434,340	07/18/1995	Krimpenfort et al.
	5,443,953	08/22/1995	Hansen et al.
	5,464,764	11/07/1995	Capecchi et al.
	5,476,786	12/19/1995	Huston
	5,487,992	01/30/1996	Capecchi et al.
	5,503,998	04/02/1996	Christou et al.
	5,506,125	04/09/1996	McCabe et al.
	5,525,510	06/11/1996	McCabe et al.
	5,530,101	06/25/1996	Queen et al.
	5,545,403	08/13/1996	Page
	5,545,404	08/13/1996	Page
	5,545,405	08/13/1996	Page
	5,545,806	08/13/1996	Lonberg et al.
	5,569,825	10/29/1996	Lonberg et al.
	5,578,287	11/26/1996	Theodore et al.
	5,584,807	12/17/1996	McCabe
	5,585,089	12/17/1996	Queen et al.
	5,585,097	12/17/1996	Bolt et al.
	5,624,821	04/29/1997	Winter et al.
	5,639,947	06/17/1997	Hiatt et al.
	5,869,620	02/09/1999	Whitlow et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	T ²
	CA 1316852	04/27/1993	
	EP 0 045 809	08/19/1987	
	EP 0 120 694	07/21/1993	
	EP 0 125 023	06/05/1991	
	EP 0 173 552	03/05/1986	
	EP 0 239 400	09/30/1987	
	EP 0 260 148	03/16/1988	
	EP 0 319 206	06/07/1989	
	EP 0 328 404	09/29/1993	
	EP 0 338 841	10/25/1989	
	EP 0 393 045	03/29/1995	
	EP 0 411 893	02/06/1991	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary.

Complete if Known

Application Number 10/787,067

Filing Date February 25, 2004

First Named Inventor Graves, Scott

Group Art Unit 1642

Examiner Name Unknown

Sheet 3 of 7

Attorney Docket No: 295.061US4

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	T ²
	EP 0 451 216	01/24/1996	
	EP 0 460 167	10/11/1995	
	EP 0 520 962	12/30/1992	
	EP 0 578 515	01/12/1994	
	EP 0 592 106	04/13/1994	
	EP 0 614 982	09/14/1994	
	EP 0 682 040	11/15/1995	
	EP 0 699 755	03/06/1996	
	GB 2188638	10/07/1987	
	WO 84/03712	09/27/1984	
	WO 86/01533	03/13/1986	
	WO 86/02097	04/10/1986	
	WO 86/05807	10/09/1986	
	WO 87/04462	07/30/1987	
	WO 88/01649	03/10/1988	
	WO 88/06630	09/07/1988	
	WO 89/01036	02/09/1989	
	WO 89/09825	10/19/1989	
	WO 89/10404	11/02/1989	
	WO 90/04036	04/19/1990	
	WO 90/10457	09/20/1990	
	WO 91/06320	05/16/1991	
	WO 91/06657	05/16/1991	
	WO 91/09967	07/11/1991	
	WO 92/04381	03/19/1992	
	WO 92/11018	07/09/1992	
	WO 92/15683	09/17/1992	
	WO 92/22653	12/23/1992	
	WO 93/08300	04/29/1993	
	WO 93/11238	06/10/1993	
	WO 93/12246	06/24/1993	
	WO 93/16185	08/19/1993	
	WO 93/17105	09/02/1993	
	WO 93/22332	11/11/1993	
	WO 93/22442	11/11/1993	
	WO 93/23537	11/25/1993	
	WO 93/25240	12/23/1993	
	WO 94/04679	03/03/1994	
	WO 94/09131	04/28/1994	
	WO 94/12625	06/09/1994	
	WO 94/22902	10/13/1994	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 10/787,067

Filing Date February 25, 2004

First Named Inventor Graves, Scott

Group Art Unit 1642

Examiner Name Unknown

Sheet 4 of 7

Attorney Docket No: 295.061US4

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	T ²
	WO 94/29451	12/22/1994	
	WO 95/08577	03/30/1995	
	WO 95/15335	06/08/1995	
	WO 95/15341	06/08/1995	
	WO 95/15769	06/15/1995	
	WO 95/20672	08/03/1995	WPI Acc. No. 95-275457
	WO 95/25167	09/21/1995	
	WO 96/05228	02/22/1996	
	WO 96/11013	04/18/1996	
	WO 96/27011	09/06/1996	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	ABRAHAM, "The Influence of Periodate Oxidation on Monoclonal Antibody Avidity and Immunoreactivity", <u>Journal of Immunological Methods</u> , 144, 77-86 (1991).
	BETTER, "Escherichia Coli Secretion of an Active Chimeric Antibody FragmentT", <u>Science</u> , 240, 1041-1043 (1988).
	BREKKE et al., "The Structural Requirements for Complement Activation by IgC: Does it Hinge on the Hinge?", <u>Immunology Today</u> , 16, 85-90 (1995).
	BRUGGEMANN et al., "Comparison of the Effector Functions of Human Immunoglobulins Using a Matched Set of Chimeric Antibodies", <u>J. Exp. Med.</u> , 166, 1351-1361 (1987).
	CANFIELD et al., "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the Ch2 Domain and is Modulated by the Hinge Region", <u>J. Exp. Med.</u> , 173, 1483-1491 (1991).
	CARON et al., "Biological and Immunological Features of Humanized M195 (anti-CD33) Monoclonal Antibodies", <u>Cancer Research</u> , 52, 6761-6767 (1992).
	CO et al., "Genetically Engineered Deglycosylation of the Variable Domain Increases the Affinity of an Anti-CD 33 Monoclonal Antibody", <u>Molecular Immunology</u> , 30, 1361-1367 (1993).
	COUTO et al., "Cloning of cDNAs Encoding the Variable Domains of Antibody KC4G3 and Construction of a Chimeric Antibody", <u>Hybridoma</u> , 12, 485-489 (1993).
	DAVIS et al., "Glycosylation Governs the Binding of Antipeptide Antibodies to Regions of Hypervariable Amino Acid Sequence Within Recombinant GP120 of Human Immunodeficiency Virus Type 1", <u>Journal of General Virology</u> , 71, 2889-2898 (1990).
	DORAI et al., "Aglycosylated Chimeric Mouse/Human IgG1 Antibody Retains Some Effector Functions", <u>Hybridoma</u> , 10, 211-217 (1991).
	DUNCAN et al., "The Binding Site for C1q on IgG", <u>Nature</u> , 332, 738-740 (1988).
	DWEK et al., "Glycobiology: The Function of Sugar in the IgG Molecule", <u>The Journal of Anatomy</u> , 187, 279-292 (1995).
	ENDO et al., "Glycosylation of the Variable Region of Immunoglobulin G Site Specific Maturation of the Sugar Chains", <u>Molecular Immunology</u> , 32, 931-940 (1995).

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it carries a valid OMB control number.

(Use as many sheets as necessary)

Complete if Known

Examiner Name	Unknown
---------------	---------

Sheet 5 of 7

Attorney Docket No: 295.061US4

Examiner
Initials*

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

GEYSEN et al., "Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid". PNAS. 81, 3998-4002 (1984).

GOSHORN, "Preclinical Development of huNR-LU-10, a Humanized Antibody for Tumor Targeting", Immunotechnology, 2, 300 (1996).

GREENMAN et al., "The Use of Intracellular Single-Chain Antibody Fragments to Inhibit Specifically the Expression of Cell Surface Molecules", Journal of Immunological Methods, 194, 169-180 (1996).

GREENSPAN et al., "Defining Epitopes: It's Not as Easy as it Seems", Nature Biotechnology, 17, 936-937 (1999).

HAND et al., "Comparative Biological Properties of a Recombinant Chimeric Anti-Carcinoma mAb and a Recombinant Aglycosylated Variant", Cancer Immunology Immunotherapy, **35**, 165-174 (1992).

HELFRICH et al., "Epitope Mapping of SCLC-Cluster-2 Mabs and Generation of Antibodies Directed Against New EGP-2 Epitopes", *Int. J. Cancer Suppl.*, 8, 64-69 (1994).

HERLYN et al., "CO 17-1A and Related Monoclonal Antibodies: Their Production and Characterization". *Hybridoma*, 5(Suppl. 1), S3-S10 (1986).

HEYMAN et al., "Carbohydrate Chains on IgG2b: A Requirement for Efficient Feedback Immunosuppression". *The Journal of Immunology*, 134, 4018-4023 (1985).

HOUBA et al., "Improved Characteristics of a Human B-Glucuronidase-Antibody Conjugate After Decycosylation for Use in Antibody-Directed Enzyme Prodrug Therapy", Bioconjugate Chem., **7**, 606-611 (1996).

KABAT, "The Structural Basis of Antibody Complementarity", *Adv Protein Chem*, **32**, 1-75 (1978).

LEIJ et al., "SCLC-Cluster-2 Antibodies Detect the Pancarcinoma/Epithelial Glycoprotein EGP-2", International Journal of Cancer, Supplement, 8, 60-63 (1994).

LEUNG et al., "Construction and Characterization of a Humanized, Internalizing, B-Cell (CD22)-Specific, Leukemia/Lymphoma Antibody LL2", *Molecular Immunology*, 32, 1413-1427 (1995).

LITVINOV et al., "Ep-CAM: A Human Epithelial Antigen Is a Homophilic Cell-Cell Adhesion Molecule". *The Journal of Cell Biology*, 125, 437-446 (1994).

LUND et al., "Control of IgG/Fc Glycosylation: A Comparison of Oligosaccharides From Chimeric Human/Mouse and Mouse Subclass Immunoglobulin", Molecular Immunology, 30, 741-748 (1993).

MA et al., "Immunotherapeutic Potential of Antibodies Produced in Plants", Trends in Biotechnology, 13, 522-527 (1995).

MCCLOSKEY et al., "Human Constant Regions Influence the Antibody Binding Characteristics of Mouse-Human Chimeric IgG Subclasses", Immunology, 88, 169-173 (1996).

MORGAN et al., "The N-Terminal End of the CH2 Domain of Chimeric Human IgG: Anti-HLA-DR is Necessary for C1q, FcγR1 and FcγRI and FcγRIII Binding", *Immunology*, 86, 319-324 (1995).

MORRISON et al., "Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains", PNAS, 81, 6851-6855 (1984).

MORRISON et al., "In vitro Antibodies: Strategies for Production and Application", Annu. Rev. Immunol., 10, 239-265 (1992).

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/787,067
Filing Date	February 25, 2004
First Named Inventor	Graves, Scott
Group Art Unit	1642
Examiner Name	Unknown

Sheet 6 of 7

Attorney Docket No: 295.061US4

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	MURAOKA et al., "Structural Requirements for IgM Assembly and Cytolytic Activity", <u>The Journal of Immunology</u> , 142, 695-701 (1989).
	NISHIMURA et al., "Recombinant Human-Mouse Chimeric Monoclonal Antibody Specific for Common Acute Lymphocytic Leukemia Antigen", <u>Cancer Research</u> , 47, 999-1005 (1987).
	NOSE et al., "Biological Significance of Carbohydrate Chains on Monoclonal Antibodies", <u>PNAS</u> , 80, 6632-6636 (1983).
	PEAKE et al., "Does Non-Enzymatic Glycosylation Affect Complement Function in Diabetes?", <u>Diabetes Research</u> , 11, 109-114 (1989).
	PLUCKTHUN et al., "New Protein Engineering Approaches to Multivalent and Bispecific Antibody Fragments", <u>Immunotechnology</u> , 3, 83-105 (1997).
	POUND et al., "Aglycosylated Chimaeric Human IgG3 Can Trigger the Human Phagocyte Respiratory Burst", <u>Molecular Immunology</u> , 30, 233-241 (1993).
	RODWELL et al., "Engineering Monoclonal Antibodies", <u>Nature</u> , 342, 99-100 (1989).
	SARMAY et al., "Mapping and Comparison of the Interaction Sites on the Fc Region of IgG Responsible for Triggering Antibody Dependent Cellular Cytotoxicity (ADCC) Through Different Types of Human Fcγ Receptor", <u>Molecular Immunology</u> , 29, 633-639 (1992).
	STRNAD et al., "Molecular Cloning and Characterization of a Human Adenocarcinoma/Epithelial Cell Surface Antigen Complementary DNA", <u>Cancer Research</u> , 49, 314-317 (1989).
	SZALA et al., "Molecular Cloning of cDNA for the Carcinoma-Associated Antigen GA733-2", <u>PNAS</u> , 87, 3542-3546 (1990).
	TACHIBANA et al., "Identification of Hybrid-Type Carbohydrate Chains on the Light Chain of Human Monoclonal Antibody Specific to Lung Adenocarcinoma", <u>Biochimica et Biophysica Acta</u> , 1182, 257-263 (1993).
	TAMS et al., "Mild Chemical Deglycosylation of Horseradish Peroxidase Yields a Fully Active, Homogeneous Enzyme", <u>Analytical Biochemistry</u> , 228, 48-55 (1995).
	TAO et al., "Studies of Aglycosylated Chimeric Mouse-Human IgG - Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region", <u>The Journal of Immunology</u> , 143, 2595-2601 (1989).
	TAO et al., "The Differential Ability of Human IgG1 AND IgG4 to Activate Complement is Determined by the COOH-Terminal Sequence of the Ch2 Domain", <u>J. Exp. Med.</u> , 173, 1025-1028 (1991).
	TAYLOR et al., "Altered Glycosylation and Selected Mutation in Recombinant Human Complement Component C9: Effects on Haemolytic Activity", <u>Immunology</u> , 83, 501-506 (1994).
	VERHOEYEN et al., "Engineering of Antibodies", <u>BioAssays</u> , 8, 74-78 (1988).
	WEIDEN et al., "Rhenium-186-Labeled Chimeric Antibody NR-LU-13: Pharmacokinetics, Biodistribution and Immunogenicity Relative to Murine Analog NR-LU-10", <u>J Nucl Med</u> , 34, 2111-2119 (1993).
	WINKELHAKE et al., "Effects of pH Treatments and Deglycosylation of Rabbit Immunoglobulin G on the Binding of C1q", <u>The Journal of Biological Chemistry</u> , 255, 2822-2828 (1980).
	WOOF et al., "The Role of Glycosylation in Antibody Effector Function", <u>GlycoNews Second</u> , 94, 1-4 (1994).

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: center;"><i>Complete if Known</i></td> </tr> <tr> <td style="width: 40%;">Application Number</td> <td>10/787,067</td> </tr> <tr> <td>Filing Date</td> <td>February 25, 2004</td> </tr> <tr> <td>First Named Inventor</td> <td>Graves, Scott</td> </tr> <tr> <td>Group Art Unit</td> <td>1642</td> </tr> <tr> <td>Examiner Name</td> <td>Unknown</td> </tr> </table>	<i>Complete if Known</i>		Application Number	10/787,067	Filing Date	February 25, 2004	First Named Inventor	Graves, Scott	Group Art Unit	1642	Examiner Name	Unknown
<i>Complete if Known</i>													
Application Number	10/787,067												
Filing Date	February 25, 2004												
First Named Inventor	Graves, Scott												
Group Art Unit	1642												
Examiner Name	Unknown												
Sheet 7 of 7	Attorney Docket No: 295.061US4												

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	XIA et al., "Efficient Complement-Mediated Lysis of Cells Containing the Campath-1 (CDw52) Antigen", <u>Molecular Immunology</u> , 30, 1089-1096 (1993).
	XIA et al., "Structure of the CAMPATH-1 Antigen, a Glycosylphosphatidylinositol-Anchored Glycoprotein Which is an Exceptionally Good Target for Complement Lysis", <u>Biochemical Journal</u> , 293, 633-640 (1993).
	YOSHIDA et al., "Mutants of Dictyostelium Discoideum With Altered Carbohydrate Moieties of Contact Site A", <u>Cell Structure and Function</u> , 16, 383-390 (1991).

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached